Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis
Authors
Keywords
-
Journal
LIVER INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-03-31
DOI
10.1111/liv.14888
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Branched-Chain Amino Acids in relation to Food Preferences and Insulin Resistance in Obese Subjects Consuming Walnuts: A Cross-Over, Randomized, Double-Blind, Placebo-Controlled inpatient physiology study
- (2021) Dario Tuccinardi et al. CLINICAL NUTRITION
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
- (2020) A. Mantovani et al. DIABETES & METABOLISM
- Established and emerging factors affecting the progression of nonalcoholic fatty liver disease
- (2020) Stergios Kechagias et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
- (2020) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
- (2020) Jean-François Dufour et al. GUT
- Hepatic lipid droplet homeostasis and fatty liver disease
- (2020) Fabian Seebacher et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
- (2020) Nikolaos Perakakis et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
- (2019) Joan Khoo et al. LIVER INTERNATIONAL
- Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway
- (2019) Zhi Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement
- (2019) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD
- (2019) Stergios A Polyzos et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study
- (2019) Nikolaos Perakakis et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data
- (2018) Jasmine Chong et al. BIOINFORMATICS
- Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis
- (2018) Giovanni Musso et al. GASTROENTEROLOGY
- Pharmacotherapy of type 2 diabetes: An update
- (2018) Jagriti Upadhyay et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Branched-chain amino acids in health and disease: metabolism, alterations in blood plasma, and as supplements
- (2018) Milan Holeček Nutrition & Metabolism
- Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
- (2018) Kirstine S Tølbøl et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics
- (2018) Nikolaos Perakakis et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
- (2018) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Pharmacotherapy of obesity: Available medications and drugs under investigation
- (2018) Eleni Pilitsi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice
- (2017) Takashi Honda et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Mechanisms of hepatic stellate cell activation
- (2017) Takuma Tsuchida et al. Nature Reviews Gastroenterology & Hepatology
- Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients
- (2017) Franck Chiappini et al. Scientific Reports
- GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway
- (2016) Qin He et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
- (2016) Juan P. Arab et al. HEPATOLOGY
- Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway
- (2016) Wenxin Tong et al. HEPATOLOGY RESEARCH
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK
- (2013) Lili Zhang et al. LIVER INTERNATIONAL
- Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease
- (2013) April D. Lake et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
- (2011) Shvetank Sharma et al. PLoS One
- SnapShot: Reactive Oxygen Intermediates (ROI)
- (2010) Carl Nathan et al. CELL
- Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
- (2010) Ariel E. Feldstein et al. JOURNAL OF LIPID RESEARCH
- Bile acid levels are increased in the liver of patients with steatohepatitis
- (2009) Márcia M. Aranha et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More